Opevesostat combinations for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has spread to other parts of the body and has gotten worse despite hormone therapy (like having your testosterone lowered).
- You should have already tried 1 or 2 newer hormone medicines (such as abiraterone or enzalutamide) and your cancer kept growing while or after using them.
- You cannot have serious heart or blood vessel problems in the last 6 months (like a heart attack, stroke, or chest pain).
- You cannot have pituitary gland problems or adrenal insufficiency (where your body doesn't make enough stress hormones).
- Other health issues like poorly controlled diabetes, active infections, or other cancers that need treatment in the past 3 years may disqualify you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.